See more : MirLand Development Corporation Plc (MLD.TA) Income Statement Analysis – Financial Results
Complete financial analysis of AlzeCure Pharma AB (publ) (ALZCUR.ST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AlzeCure Pharma AB (publ), a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Renault SA (RNLSY) Income Statement Analysis – Financial Results
- The Allstate Corporation (ALL) Income Statement Analysis – Financial Results
- GreenSky, Inc. (GSKY) Income Statement Analysis – Financial Results
- Hydrogen Utopia International PLC (HUI.AQ) Income Statement Analysis – Financial Results
- Home Reit Plc (HOME.L) Income Statement Analysis – Financial Results
AlzeCure Pharma AB (publ) (ALZCUR.ST)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.alzecurepharma.se
About AlzeCure Pharma AB (publ)
AlzeCure Pharma AB (publ), a pharmaceutical company, develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is developing drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its pipeline drug candidates include ACD856, which is in phase I clinical trial for Alzheimer's disease, sleep disorders, traumatic brain injuries, and Parkinson's disease; ACD857, ACD679, and ACD680 for Alzheimer's disease; ACD440, a TRPV1 antagonist that has completed phase I clinical trial for neuropathic pain; and TrkA-NAM for osteoarthritic pain. The company was founded in 2012 and is based in Huddinge, Sweden.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 883.39K |
| Cost of Revenue | 476.00K | 570.00K | 576.00K | 495.00K | 44.79M | 104.00K | 8.00K |
| Gross Profit | -476.00K | -570.00K | -576.00K | -495.00K | -44.79M | -104.00K | 875.39K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 99.09% |
| Research & Development | 27.23M | 46.18M | 66.72M | 62.36M | 44.79M | 36.83M | 10.97M |
| General & Administrative | 10.60M | 10.17M | 11.27M | 9.38M | 6.04M | 32.50M | 733.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.60M | 10.17M | 11.27M | 9.38M | 6.04M | 32.50M | 733.00K |
| Other Expenses | -43.00K | 218.00K | 163.00K | 291.00K | 181.00K | 3.64M | -939.00K |
| Operating Expenses | 38.26M | 56.57M | 78.14M | 72.02M | 51.01M | 36.14M | 10.77M |
| Cost & Expenses | 38.26M | 56.57M | 78.14M | 72.02M | 51.01M | 36.14M | 10.77M |
| Interest Income | 1.10M | 207.00K | 146.00K | 214.00K | 199.00K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 4.00K | 1.00K | 1.00K | 149.00K | 92.00K | 55.00K |
| Depreciation & Amortization | 476.00K | 570.00K | 576.00K | 495.00K | 290.00K | 104.00K | 8.00K |
| EBITDA | -37.87M | -55.67M | -77.21M | -70.87M | -50.57M | -36.04M | -10.81M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,217.93% |
| Operating Income | -38.26M | -56.44M | -77.93M | -71.58M | -50.91M | -35.89M | -10.77M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,218.83% |
| Total Other Income/Expenses | 1.10M | 203.00K | 145.00K | 213.00K | 50.00K | -92.00K | -883.23K |
| Income Before Tax | -37.17M | -56.24M | -77.78M | -71.37M | -50.86M | -35.99M | -10.82M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,225.06% |
| Income Tax Expense | 0.00 | -203.00K | 1.00K | 1.00K | 149.00K | 246.00K | 0.00 |
| Net Income | -37.17M | -56.04M | -77.78M | -71.37M | -51.01M | -35.99M | -10.82M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,225.06% |
| EPS | -0.60 | -1.17 | -1.98 | -1.82 | -1.30 | -1.52 | -0.57 |
| EPS Diluted | -0.60 | -1.17 | -1.98 | -1.82 | -1.30 | -1.52 | -0.57 |
| Weighted Avg Shares Out | 61.95M | 47.70M | 39.32M | 39.32M | 39.32M | 23.71M | 18.89M |
| Weighted Avg Shares Out (Dil) | 62.09M | 47.70M | 39.32M | 39.32M | 39.32M | 23.71M | 18.89M |
Source: https://incomestatements.info
Category: Stock Reports